Mutational analysis of BCR::ABL1 kinase domain (KD) is a crucial component of clinical decision algorithms for chronic myeloid leukemia (CML) patients with failure or warning responses to tyrosine kinase inhibitor (TKI) therapy. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.